Amgen Inc. AMGN | NASDAQ
After Hours
Company Overview:
10 Year Performance Metrics:
AMGN Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
AMGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
AMGN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
AMGN Dividends Info:
AMGN Dividend History: Dates, Payments & Yield list
Below is a schedule of all AMGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 05/16/2025 | 06/06/2025 | $2.380 | 3.26% | 3.35% | $283.78 |
| 02/14/2025 | 03/07/2025 | $2.380 | 3.14% | 3.27% | $291.16 |
| 11/18/2024 | 12/09/2024 | $2.250 | 3.23% | 3.23% | $278.76 |
| 08/16/2024 | 09/06/2024 | $2.250 | 2.76% | 2.8% | $321.44 |
| 05/17/2024 | 06/07/2024 | $2.250 | 0% | 0% | $0.00 |
| 05/16/2024 | 06/07/2024 | $2.250 | 2.78% | 2.86% | $314.72 |
| 02/15/2024 | 03/07/2024 | $2.250 | 2.99% | 3.11% | $289.07 |
| 11/16/2023 | 12/08/2023 | $2.130 | 3.17% | 3.17% | $269.00 |
| 08/17/2023 | 09/08/2023 | $2.130 | 3.16% | 3.23% | $263.85 |
| 05/17/2023 | 06/08/2023 | $2.130 | 3.62% | 3.79% | $225.02 |
| 02/14/2023 | 03/08/2023 | $2.130 | 3.3% | 3.53% | $241.03 |
| 11/16/2022 | 12/08/2022 | $1.940 | 2.73% | 2.73% | $283.77 |
| 08/17/2022 | 09/08/2022 | $1.940 | 3.03% | 3.1% | $250.58 |
| 05/16/2022 | 06/08/2022 | $1.940 | 3.03% | 3.18% | $243.87 |
| 02/14/2022 | 03/08/2022 | $1.940 | 3.22% | 3.46% | $224.27 |
| 11/15/2021 | 12/08/2021 | $1.760 | 3.39% | 3.39% | $207.40 |
| 08/16/2021 | 09/08/2021 | $1.760 | 2.98% | 3.05% | $231.07 |
| 05/14/2021 | 06/08/2021 | $1.760 | 2.67% | 2.8% | $251.38 |
| 02/11/2021 | 03/08/2021 | $1.760 | 2.79% | 3% | $235.04 |
| 11/13/2020 | 12/08/2020 | $1.600 | 2.7% | 2.7% | $237.36 |
| 08/14/2020 | 09/08/2020 | $1.600 | 2.61% | 2.67% | $239.71 |
| 05/15/2020 | 06/08/2020 | $1.600 | 2.54% | 2.66% | $240.20 |
| 02/13/2020 | 03/06/2020 | $1.600 | 2.67% | 2.87% | $223.04 |
| 11/14/2019 | 12/06/2019 | $1.450 | 2.65% | 2.65% | $218.50 |
| 08/14/2019 | 09/06/2019 | $1.450 | 2.85% | 2.92% | $198.87 |
| 05/16/2019 | 06/07/2019 | $1.450 | 3.26% | 3.41% | $169.92 |
| 02/14/2019 | 03/08/2019 | $1.450 | 2.9% | 3.11% | $186.68 |
| 11/15/2018 | 12/07/2018 | $1.320 | 2.74% | 2.74% | $192.45 |
| 08/16/2018 | 09/07/2018 | $1.320 | 2.6% | 2.69% | $196.44 |
| 05/16/2018 | 06/08/2018 | $1.320 | 2.84% | 3.04% | $173.80 |
| 02/14/2018 | 03/08/2018 | $1.320 | 2.66% | 2.94% | $179.52 |
| 11/16/2017 | 12/08/2017 | $1.150 | 2.69% | 2.69% | $170.77 |
| 08/15/2017 | 09/08/2017 | $1.150 | 2.62% | 2.71% | $170.04 |
| 05/15/2017 | 06/08/2017 | $1.150 | 2.69% | 2.88% | $159.97 |
| 02/13/2017 | 03/08/2017 | $1.150 | 2.48% | 2.74% | $167.66 |
| 11/14/2016 | 12/08/2016 | $1.000 | 2.73% | 2.73% | $146.42 |
| 08/15/2016 | 09/08/2016 | $1.000 | 2.17% | 2.29% | $174.58 |
| 05/13/2016 | 06/08/2016 | $1.000 | 2.35% | 2.63% | $152.35 |
| 02/11/2016 | 03/08/2016 | $1.000 | 2.38% | 2.83% | $141.46 |
| 11/12/2015 | 12/07/2015 | $0.790 | 2.09% | 2.09% | $150.98 |
| 08/13/2015 | 09/08/2015 | $0.790 | 1.77% | 1.87% | $168.58 |
| 05/12/2015 | 06/05/2015 | $0.790 | 1.77% | 2% | $158.24 |
| 02/10/2015 | 03/06/2015 | $0.790 | 1.72% | 2.07% | $152.57 |
| 11/10/2014 | 12/05/2014 | $0.610 | 1.5% | 1.5% | $163.09 |
| 08/12/2014 | 09/05/2014 | $0.610 | 1.82% | 1.93% | $126.32 |
| 05/13/2014 | 06/06/2014 | $0.610 | 1.95% | 2.2% | $110.81 |
| 02/11/2014 | 03/07/2014 | $0.610 | 1.67% | 2.01% | $121.24 |
| 11/12/2013 | 12/06/2013 | $0.470 | 1.67% | 1.67% | $112.71 |
| 08/14/2013 | 09/06/2013 | $0.470 | 1.66% | 1.76% | $106.64 |
| 05/14/2013 | 06/07/2013 | $0.470 | 1.54% | 1.74% | $107.94 |
| 02/11/2013 | 03/07/2013 | $0.470 | 1.83% | 2.21% | $84.92 |
| 11/13/2012 | 12/07/2012 | $0.360 | 1.68% | 1.68% | $85.77 |
| 08/14/2012 | 09/07/2012 | $0.360 | 1.63% | 1.72% | $83.54 |
| 05/14/2012 | 06/07/2012 | $0.360 | 1.82% | 2.05% | $70.20 |
| 02/13/2012 | 03/07/2012 | $0.360 | 1.35% | 2.11% | $68.20 |
| 11/15/2011 | 12/08/2011 | $0.280 | 0.99% | 1.98% | $56.59 |
| 08/16/2011 | 09/08/2011 | $0.280 | 0.55% | 2.18% | $51.27 |
Projected Future Returns & Dividends for AMGN
Based on past 10-year performance, here are AMGN growth metrics:
Share price CAGR of +5.87%
Dividend CAGR of +11.66%
Using AMGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| AMGN (DRIP) | AMGN - No DRIP | |
|---|---|---|
| Current Price | $283.78 | $283.78 |
| Start Shares | 35.24 | 35.24 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 54.11 | 35.24 |
| Dividends Payment | $7.17 | $7.17 |
| Annual Dividends | $1,552 | $1,011 |
| Yield on cost | 15.52% | 10.11% |
| Share Price | $474.33 | $474.33 |
| Total Dividends | $7,332 | $5,791 |
| Final Value | $25,665 | $22,506 |
NOTE: Above numbers are our estimate based on AMGN's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Amgen Inc. (AMGN) had its IPO on 1983-06-17, and is trader on NASDAQ stock exchange.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN website: https://www.amgen.com
